AstraZeneca has announced data showing its cancer drug Calquence outperformed standard care in chronic lymphocytic leukaemia – reducing risk of disease progression or death by 69%.
Janssen has signed a licence and option deal with Denmark’s Genmab to develop a next-generation drug that it hopes will outperform its already-marketed Darzalex in multiple myeloma, and oth
The FDA has quickly approved a new antibody treatment for an aggressive form of lymphoma from Roche – costing in the region of $90,000 for a four-month course.
